Switzerland· 27867014
Metopiron, Kapseln
A metyrapone product containing metyraponum, registered in Switzerland by EffRx Pharmaceuticals SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Metyrapone is registered in 14 of 19 countries.
Countries holding a registration under ATC V04CD01 (metyrapone), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Metyrapone · ATC V04CD01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of metyrapone costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- Switzerland: $91.87 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Metyrapone · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$91.87
- FR France$70.58
The record
At a glance
Swissmedic (Switzerland)- Active substance
- metyraponum
- Manufacturer
- EffRx Pharmaceuticals SA
- Country
- Switzerland (CH)
- ATC code
- V04CD01
- ATC class
- Metyrapone
- Defined daily dose
- 3 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin768027867014850 StkCHF 317.45
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
14 interactions on record for metyrapone.
Graded by severity as the source publishes them — 14 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metyrapone · interactions on record
14 records
- 14 moderate
Most severe, free to view
- CyproheptadinA15AA01moderate
- EstradiolD11AX34moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Desogestrel and ethinylestradiolG03AA09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Metyrapone in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMetopirone 250mg capsulesEsteve RD UK & Ireland Ltd
- NetherlandsMetopirone 250 mg capsules, zachtEsteve Pharmaceuticals S.A.
- GermanyMetopironEsteve Pharmaceuticals, S.A.
- CzechiaMETOPIRONEEsteve Pharmaceuticals S.A., Barcelona
- United StatesMetopironeESTEVE PHARMACEUTICALS, S.A.
- BelgiumMetycor 250 mgHRA Pharma France
- ItalyCORMETO*50 cps molli 250 mg flaconeESTEVE PHARMACEUTICALS SA
- NorwayMetycorEsteve Pharmaceuticals S.A
Authorised across Europe · EMA
The same active substance is authorised in 24 EEA countries. Names it is sold under:
- Austria · Metycor
- Bulgaria · Metopirone
- Czechia · Metopirone
- Germany · Metopiron
- Denmark · Metopirone
- Estonia · Cormeto
- Spain · Metopirone
- Finland · Metopirone
- France · Metyrapone Esteve
- Greece · Metopirone
- Croatia · Metopirone
- Hungary · Cormeto
- Ireland · Metopirone
- Italy · Cormeto
- Lithuania · Cormeto
- Latvia · Metopirone
- Netherlands · Metopirone
- Norway · Metycor
- Poland · Metopirone
- Portugal · Metopirone Esteve Pharmaceuticals
- Romania · Metopirone
- Sweden · Metopirone
- Slovenia · Metycor
- Slovakia · Metopirone
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d013e992-9ce5-4a9b-b3d6-e56faaa01024 GET /v1/drugs/d013e992-9ce5-4a9b-b3d6-e56faaa01024?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "metyraponum 250 mg",
"valid_from": "2015-06-01",
"limitations": "[{\"description\":\"Zur Behandlung des Cushing-Syndroms bei nicht diagnostizierbarer Ursache des Hypercortisolismus, bei transitorisch oder persistierend inoperablen Patienten oder in Kombination mit einer Strahlentherapie.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2015-06-01\"}]",
"galenic_form": "Kaps 250 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2015-06-01",
"self_retention_pct": 10
}See everything about metyrapone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.